title: Lack of tolerance and physical dependence upon repeated treatment with the novel hypnotic zolpidem.
abstract: Zolpidem is a new, short-acting hypnotic of imidazopyridine structure which binds selectively to a subpopulation of receptors involved in the action of benzodiazepines [omega 1 (BZ1) sites of the gamma-aminobutyric acidA receptors]. The present study investigated whether tolerance and physical dependence develop after repeated treatment with zolpidem as is observed with benzodiazepines. Mice were given zolpidem or the benzodiazepine midazolam (2 x 30 mg/kg, p.o.) for 10 consecutive days. Tolerance to central depressant effects (evaluated by recording spontaneous locomotor activity) and to anticonvulsant effects (measured against pentylenetetrazole-, electroshock- and isoniazid-induced convulsions) was assessed 42 hr after the last administration. A decrease in the latency to isoniazid-induced convulsions was taken as an index of physical dependence and was evaluated 3, 6, 14, 24, 42 and 67 hr after the end of chronic drug treatment. Repeated treatment with midazolam produced tolerance to its sedative and anticonvulsant activities as indicated by shifts of the dose-response curves by a factor of 3 to 5. Fourteen hr after discontinuation of treatment, spontaneous withdrawal was observed and lasted 3 days. When flumazenil was given 3 or 6 hr after the final midazolam injection, precipitated withdrawal was observed. In contrast, after repeated treatment with zolpidem, there was no change in its ability to produce sedative and anticonvulsant effects. Moreover, neither spontaneous nor flumazenil-induced precipitated withdrawal was observed in zolpidem-treated mice.
authors.affiliation: Synthelabo Recherche (L.E.R.S.), Bagneux, France.
authors.forename: G
authors.initials: G
authors.lastname: Perrault
authors.forename: E
authors.initials: E
authors.lastname: Morel
authors.forename: D J
authors.initials: DJ
authors.lastname: Sanger
authors.forename: B
authors.initials: B
authors.lastname: Zivkovic
mesh_terms: D000818:Animals; D004361:Drug Tolerance; D004597:Electroshock; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007538:Isoniazid / Q000633:toxicity; D008297:Male; D051379:Mice; D008874:Midazolam / Q000627:therapeutic use; D009043:Motor Activity / Q000187:drug effects; D011725:Pyridines / Q000627:therapeutic use*; D012640:Seizures / Q000139:chemically induced / Q000517:prevention & control*; D019966:Substance-Related Disorders; D013997:Time Factors; D000077334:Zolpidem
chemical_list: D006993:Hypnotics and Sedatives; D011725:Pyridines; D000077334:Zolpidem; D008874:Midazolam; D007538:Isoniazid